Natixis Advisors LLC Has $23.10 Million Position in Bristol-Myers Squibb (NYSE:BMY)

Natixis Advisors LLC lifted its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 34.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 446,364 shares of the biopharmaceutical company's stock after acquiring an additional 115,361 shares during the period. Natixis Advisors LLC's holdings in Bristol-Myers Squibb were worth $23,095,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Reston Wealth Management LLC acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $25,000. Hollencrest Capital Management lifted its holdings in shares of Bristol-Myers Squibb by 61.3% during the third quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 187 shares during the last quarter. Kennebec Savings Bank acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth $28,000. Valued Wealth Advisors LLC raised its stake in Bristol-Myers Squibb by 1,168.1% during the 3rd quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 549 shares during the last quarter. Finally, ORG Wealth Partners LLC bought a new stake in Bristol-Myers Squibb in the 3rd quarter valued at $34,000. 76.41% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on BMY. Leerink Partners raised Bristol-Myers Squibb from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. UBS Group lifted their price target on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a "neutral" rating in a report on Wednesday, October 9th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a "hold" rating for the company in a research note on Tuesday, July 23rd. Morgan Stanley lifted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an "underweight" rating in a research report on Tuesday, November 12th. Finally, Jefferies Financial Group upped their price target on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a "hold" rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $54.07.

Bristol-Myers Squibb Stock Up 2.7 %

BMY traded up $1.54 during trading on Tuesday, hitting $58.34. The company had a trading volume of 5,438,848 shares, compared to its average volume of 14,404,651. The firm's 50-day moving average price is $52.90 and its 200 day moving average price is $47.37. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The company has a market capitalization of $118.32 billion, a PE ratio of -16.08, a PEG ratio of 15.08 and a beta of 0.44. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to analysts' expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm posted $2.00 EPS. As a group, equities analysts expect that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.11%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb's payout ratio is presently -66.85%.

Insider Activity at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now directly owns 62,109 shares of the company's stock, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the firm's stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.